ライフサイエンスコーパス: non-communicable disease

1 untries (around 80% of DALYs attributable to non-communicable disease).

2 Obesity is a common cause of non-communicable disease.

3 c, where three-quarters of mortality is from non-communicable disease.

4 nd which has a growing prevalence of chronic non-communicable disease.

5 on could be a risk of development of chronic non communicable diseases.

6 e are no detailed assessments of late-onset, non-communicable diseases.

7 demiological transition from communicable to non-communicable diseases.

8 ths annually through its effects on multiple non-communicable diseases.

9 ary patterns are a global priority to reduce non-communicable diseases.

10 for beginning to confront the rising tide of non-communicable diseases.

11 l mortality, growth failure, and adult-onset non-communicable diseases.

12 ally in the context of the growing burden of non-communicable diseases.

13 , and help prevent such diet-related chronic non-communicable diseases.

14 h risk factors that include communicable and non-communicable diseases.

15 urvival and reduce disability, stunting, and non-communicable diseases.

16 contributor to adult obesity, diabetes, and non-communicable diseases.

17 als, and to address the emerging burden from non-communicable diseases.

18 al, neonatal, and nutritional causes towards non-communicable diseases.

19 s a major modifiable risk factor for chronic non-communicable diseases.

20 ld health services, but poorly in addressing non-communicable diseases.

21 se--eg, US$1029.10 for HIV/AIDS to $3.21 for non-communicable diseases.

22 tegrated into management of communicable and non-communicable diseases.

23 e future rate of decline in communicable and non-communicable diseases.

24 of added visceral fat and increased risk of non-communicable diseases.

25 y biomarkers to diagnose both infectious and non-communicable diseases.

26 l injuries, neglected tropical diseases, and non-communicable diseases.

27 increased the incidence of stroke and other non-communicable diseases.

28 d due to the increased prevalence of chronic non-communicable diseases.

29 r identifying a range of both infectious and non-communicable diseases.

30 duce the burden of cancers and other chronic non-communicable diseases.

31 s for individuals living with infectious and non-communicable diseases.

32 biome and predisposes individuals to chronic non-communicable diseases.

33 co-occurs with growing rates of diet-related non-communicable diseases.

34 isk factors for poor health trajectories and non-communicable diseases.

35 ographic and lifestyle parameters and common non-communicable diseases.

36 d Health Organization (WHO) 2025 targets for non-communicable diseases.

37 improve treatment effectiveness, and address non-communicable diseases.

38 t is associated with many more deaths due to non-communicable diseases.

39 gnitive development, and increase risks from non-communicable diseases.

40 ageing populations and the growing burden of non-communicable diseases.

41 xhibit potential biological activity against non-communicable diseases.

42 with preventing and controlling the rise of non-communicable diseases.

43 risk of hormone-sensitive cancers and other non-communicable diseases.

44 ly prevalent dual burden of communicable and non-communicable diseases.

45 such as obesity, diabetes, and other chronic non-communicable diseases.

46 gs in metabolic syndrome, diabetes and other non-communicable diseases.

47 on), with no discernible funding targeted to non-communicable diseases.

48 s part of a comprehensive strategy to reduce non-communicable diseases.

49 inflammation rooted in both communicable and non-communicable diseases.

50 s the richest 20% from a similar increase in non-communicable diseases (1.4 vs 5.3 years).

51 ction Plan for the Prevention and Control of Non-communicable Diseases 2013-2020, and in advancing th

52 rocessed meats that can lead to diet-related non-communicable diseases(5,6) while also preventing app

53 ease (-9.64%, 95% CI -6.38 to -12.90), other non-communicable diseases (-9.14%, -4.26 to -14.02), and

54 Non-communicable diseases accounted for the majority of

55 and millions of adults at increased risk of non-communicable diseases after low birthweight.

56 eterminants are relevant to communicable and non-communicable disease alike.

57 trials addressing their needs-infectious and non-communicable diseases alike.

58 n UHC, especially as countries pivot towards non-communicable disease and injury care.

59 s to reduce mortality at age 5-69 years from non-communicable disease and injury comprising the highe

60 p governments to increase their spending for non-communicable disease and mental health services and

61 coalitions play a key role in advocating for non-communicable disease and mental health services and

62 ients' quality of life living with a chronic non-communicable disease and their partners.

63 riate relationships between risk factors for non-communicable diseases and brain structure, including

64 ite the UN's political commitment to address non-communicable diseases and ensure universal access to

65 Non-communicable diseases and external causes of death,

66 continued to shift away from communicable to non-communicable diseases and from premature death to ye

67 ecognized as a major risk factor for chronic non-communicable diseases and has been estimated to cont

68 still persist in LICs--whereas the burden of non-communicable diseases and injuries has increased.

69 been learnt about prevention and control of non-communicable diseases and injuries, which is well su

70 is now confronting an increasing burden from non-communicable diseases and injuries.

71 ciation with age-standardised mortality from non-communicable diseases and injuries.

72 o exceed the incremental gains in decreasing non-communicable diseases and injury burdens of high-inc

73 om communicable diseases narrowed over time, non-communicable diseases and injury burdens varied mark

74 trends in deaths caused by communicable and non-communicable diseases and injury.

75 have pledged to tackle the growing burden of non-communicable diseases and mental health conditions,

76 significant global health burdens from both non-communicable diseases and micronutrient deficiencies

77 nearly 90% of expected disability is due to non-communicable diseases and most of the remainder to i

78 ations, while at the same time, diet-related non-communicable diseases and obesity have exponentially

79 Urgent action is now required to control non-communicable diseases and reduce fatal injuries in M

80 f the solution is city planning that reduces non-communicable diseases and road trauma while also man

81 hift of emphasis by WHO from communicable to non-communicable diseases and the adoption by the UN of

82 urden of disease shifts from communicable to non-communicable diseases and trauma-related debility, t

83 ied in various contexts (ie, pathogenesis of non-communicable diseases and treatment response), quali

84 This study shows the reversal of HIV/AIDS, non-communicable disease, and injury mortality trends in

85 eonatal, and nutritional disorders, 43% from non-communicable diseases, and 10% from injuries.

86 e mortality (age <75 years) from all causes, non-communicable diseases, and causes considered potenti

87 l health security, antimicrobial resistance, non-communicable diseases, and climate change-but also t

88 disorders increase risk for communicable and non-communicable diseases, and contribute to unintention

89 als (MDGs), addressing growing challenges of non-communicable diseases, and ensuring universal health

90 Mortality from tuberculosis, non-communicable diseases, and injuries decreased slight

91 maternal, perinatal, and nutritional causes, non-communicable diseases, and injury.

92 total budget to infectious diseases, 12% to non-communicable diseases, and less than 1% to injuries

93 sion, alongside other diseases (eg, malaria, non-communicable diseases, and maternal diseases), and g

94 easing life expectancy, rising prevalence of non-communicable diseases, and resulting polypharmacy am

95 rcinogenic agents is likely to prevent other non-communicable diseases, and the cause could be remove

96 neonatal, and nutritional disorders; second, non-communicable diseases; and third, injuries.

97 of adult mortality risks from infections and non-communicable diseases are a result of historical chi

98 Non-communicable diseases are increasingly common causes

99 the poor, which population interventions for non-communicable diseases are most applicable in differe

100 Chronic, non-communicable diseases are now recognised as diseases

101 Non-communicable diseases are the leading global cause o

102 Non-communicable diseases are, however, already major pu

103 Since this transition, the prevention of non-communicable disease as well as communicable disease

104 appearance or severity of multiple chronic, non-communicable diseases, as these diseases share the s

105 = 0.60, P = 0.048) but not for death due to non-communicable diseases (B = 17 events/g of daily sodi

106 association between socioeconomic status and non-communicable disease behavioural risk factors is wel

107 mplicated in substantial global increases in non-communicable disease burden in low-income, remote, a

108 he total disease burden in 2016, whereas the non-communicable disease burden increased.

109 With an ageing global population comes major non-communicable disease burden, especially in low-incom

110 a were developed for key nutrients linked to non communicable diseases by an independent scientific c

111 -third reduction in premature mortality from non-communicable diseases by 2030.

112 5 initiative, a plan to cut mortality due to non-communicable diseases by 25% by 2025.

113 ent Goals to reduce premature mortality from non-communicable diseases by a third by 2030.

114 ing tobacco use and premature mortality from non-communicable diseases by a third by 2030.

115 ff ect of physical inactivity on these major non-communicable diseases by estimating how much disease

116 goal to reduce rates of death from chronic (non-communicable) disease by an additional 2% every year

117 ed by later overweight increases the risk of non-communicable disease, by imposing a high metabolic l

118 nservative assumptions for each of the major non-communicable diseases, by country, to estimate how m

119 reach about half the mortality reduction in non-communicable diseases called for by the Sustainable

120 shifting burden from infectious diseases to non-communicable diseases, cancer care for all ages has

121 Among chronic non-communicable diseases, cardiometabolic diseases and

122 Burden of Disease Study 2010, the burden of non-communicable diseases (cardiovascular disease, cance

123 ely available HIV care services to integrate non-communicable disease care is of high priority.

124 the world's richest 20%, on the other hand, non-communicable diseases caused 85% of death and disabi

125 Hypertension is a non-communicable disease characterized by elevated blood

126 Bench approach and measurement-based care in non-communicable disease clinics in Malawi.

127 ing resistance, while effectively inhibiting non-communicable disease-contributing pathobionts.

128 plementation of an effective response to the non-communicable-disease crisis will need political comm

129 port injuries, cancers, cirrhosis, and other non-communicable diseases, democratic experience explain

130 ems of overweight, obesity, and diet-related non-communicable diseases (DR-NCDs) have been proposed a

131 ing individuals towards risk of Diet Related Non-communicable Diseases (DR-NCDs).

132 and child health, other infectious diseases, non-communicable diseases, Ebola, and sector-wide approa

133 able Development Goals and the challenges of non-communicable diseases, economic inequality, and clim

134 and modify the major risk factors related to non-communicable diseases, especially physical inactivit

135 DALYs from non-communicable diseases--especially ischaemic heart di

136 re prominently in the burgeoning epidemic of non-communicable diseases facing low- and middle-income

137 disorders accounted for 17.2 million deaths, non-communicable diseases for 28.1 million deaths and in

138 Asthma is one of the most common non-communicable diseases globally.

139 The burden of morbidity and mortality from non-communicable disease has risen worldwide and is acce

140 emiological evidence, the policy response to non-communicable diseases has been weak.

141 Associations between depression and non-communicable disease have been well-described.

142 High rates of non-communicable diseases have also been described with

143 However, socioeconomic factors influencing non-communicable diseases have not been included in the

144 nal, and nutritional diseases; injuries; and non-communicable diseases); health risks (tobacco smokin

145 health service use of an additional chronic non-communicable disease in different socioeconomic grou

146 btained from a community-based management of non-communicable disease in Nepal (COBIN) Wave II study,

147 Hypertension is the most common non-communicable disease in Uganda and its prevalence is

148 (ACEs) are associated with increased risk of non-communicable diseases in adulthood, potentially medi

149 Covering a large proportion of the burden of non-communicable diseases in adults, we show that family

150 cable diseases in children towards those for non-communicable diseases in adults.

151 Asthma-one of the most common chronic, non-communicable diseases in children and adults-is char

152 re than 3 million deaths per year, most from non-communicable diseases in low-income and middle-incom

153 Global and regional estimates show that non-communicable diseases in old age are rising in impor

154 communicable diseases, and the shift towards non-communicable diseases in recent decades.

155 the prevalence and overlap of infectious and non-communicable diseases in such a population in rural

156 ting, care, and treatment, and management of non-communicable diseases in the poorest populations.

157 by 2008, with 446 annual excess deaths from non-communicable diseases in the UK (280 for young peopl

158 Mortality from non-communicable diseases in the UK fell from being roug

159 is one of the most common, life-threatening, non-communicable diseases in the world and a major publi

160 ighlight the need to focus more attention on non-communicable diseases in this population and balance

161 cates early life factors in the aetiology of non-communicable diseases, including asthma/wheezing dis

162 Non-communicable diseases, including cancer, are overtak

163 ction by a third in premature mortality from non-communicable diseases, including cancer, by 2030.

164 ban regions, and has an increasing burden of non-communicable diseases, including cardiovascular dise

165 conflict includes death and disability from non-communicable diseases, including diabetes, which hav

166 lobal epidemiological trends and the rise of non-communicable diseases, including diabetes.

167 The most common non-communicable diseases, including ischaemic heart dis

168 cularly for infant deaths and mortality from non-communicable diseases, including neuropsychiatric di

169 n Africa were communicable diseases, whereas non-communicable diseases, including stroke, were consid

170 stant bacteria, mass casualty incidents, and non-communicable diseases, including thermal disorders.

171 ealthy eating guidelines that aim to prevent non-communicable diseases (increase fruits, vegetables,

172 Deaths due to non-communicable diseases increased more rapidly with ag

173 Deaths from non-communicable diseases increased over time in both se

174 As the prevalence of injuries and non-communicable diseases increases, the provision of ef

175 Non-communicable disease indicators were alarmingly high

176 recommendations: WHO's package of essential non-communicable disease interventions (PEN) and South A

177 e probability of a man or woman dying from a non-communicable disease is higher in sub-Saharan Africa

178 countries in the Gulf region, the burden of non-communicable diseases is a major threat, primarily d

179 The epidemiological transition towards non-communicable diseases is characterised by an upward

180 challenge in the prevention and treatment of non-communicable diseases is how to achieve safe, long-l

181 atus and increasing burden of mortality from non-communicable diseases is likely to become prominent.

182 ce of two or more mental or physical chronic non-communicable diseases, is a major challenge for the

183 ally in the last 30 years from infectious to non-communicable diseases, leading to major improvements

184 billions of patients suffering from chronic non-communicable disease like diabetes.

185 = 1.29; 95% CI = 1.09-1.53), diagnosis with non-communicable diseases like cancer, lung disease, hea

186 ovartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price

187 egulated at the international level, such as non-communicable diseases, mental health, and injuries.

188 ng Sustainable Development Goals 3.4 (reduce non-communicable disease morbidity by a third by 2030) a

189 evelopment Goal (SDG) 3.4-reducing premature non-communicable disease mortality by a third by 2030-sh

190 We projected that non-communicable disease mortality will increase from 28

191 cable diseases (n=131), nutrition (n=77), to non-communicable diseases (n=8), and water, sanitation,

192 Most countries have endorsed WHO non-communicable disease (NCD) best buy policies, but we

193 The non-communicable disease (NCD) burden in Kenya is not we

194 lar disease contributes substantially to the non-communicable disease (NCD) burden in low-income and

195 tle is known about the content or quality of non-communicable disease (NCD) care in humanitarian sett

196 by age and gender, by communicable (CD) and non-communicable disease (NCD) causes.

197 regression was used to analyse all-cause and non-communicable disease (NCD) mortality between 2006 an

198 The reduction by a third of premature non-communicable disease (NCD) mortality by 2030 is the

199 target 3.4, current policy and monitoring of non-communicable disease (NCD) mortality trends focus on

200 Evidence on non-communicable disease (NCD) prevalence among adults i

201 Heightened risk of non-communicable diseases (NCD) in children exposed to S

202 low-income countries, care for patients with non-communicable diseases (NCDs) and mental health condi

203 Physical non-communicable diseases (NCDs) and mental health disor

204 Non-communicable diseases (NCDs) are leading causes of p

205 Non-communicable diseases (NCDs) are rising rapidly in u

206 Behavioural risk factors of non-communicable diseases (NCDs) are socially patterned.

207 Non-communicable diseases (NCDs) are the leading cause o

208 Non-communicable diseases (NCDs) are the world's leading

209 Global efforts to highlight cancer and non-communicable diseases (NCDs) as a growing burden wer

210 educe premature mortality from the four main non-communicable diseases (NCDs) by 25% from 2010 levels

211 Non-communicable diseases (NCDs) cause a large burden of

212 Non-communicable diseases (NCDs) claim 74% of global liv

213 Non-communicable diseases (NCDs) contributed 1.45 billio

214 gical transition from infectious diseases to non-communicable diseases (NCDs) during the past three d

215 The approaches to prevention and control of non-communicable diseases (NCDs) have been elaborated in

216 However, deaths due to non-communicable diseases (NCDs) in this population rema

217 The burden of non-communicable diseases (NCDs) is disproportionately c

218 offers long-term protective effects against non-communicable diseases (NCDs) later in life in mother

219 the World Health Organization 2014 report on non-communicable diseases (NCDs) only listed smoking, al

220 economic and demographic transition, chronic non-communicable diseases (NCDs) overtake a previous bur

221 Non-communicable diseases (NCDs) such as cardiovascular

222 communities have a higher risk of dying from non-communicable diseases (NCDs) than do more advantaged

223 health are established risk factors for the non-communicable diseases (NCDs) type 2 diabetes mellitu

224 with poverty, infectious diseases, and other non-communicable diseases (NCDs), and contribute to comp

225 ributes to the development of many prevalent non-communicable diseases (NCDs), and these lifestyle-as

226 , gaps remain in quality of care, control of non-communicable diseases (NCDs), efficiency in delivery

227 re experiencing an increase in the burden of non-communicable diseases (NCDs), including cancer.

228 As with most non-communicable diseases (NCDs), oral conditions are ch

229 mplement integrated care delivery models for non-communicable diseases (NCDs), this Review explores m

230 ges of 30 years and 70 years) from four main non-communicable diseases (NCDs)--cardiovascular disease

231 people will increasingly develop age-related non-communicable diseases (NCDs).

232 provide an untapped opportunity to identify non-communicable diseases (NCDs).

233 rica, there was an increase in 70q0 for many non-communicable diseases (NCDs).

234 ansition leading to increasing prevalence of non-communicable diseases (NCDs).

235 on risk factors shared with a range of other non-communicable diseases (NCDs).

236 ria deaths; a third of premature deaths from non-communicable diseases (NCDs); and a third of those f

237 The threat of non-communicable diseases ("NCDs") is increasingly becom

238 e fraction: malaria 8.0% and syphilis 7.7%), non-communicable diseases, nutrition and lifestyle facto

239 101 319 UK Biobank participants developed a non-communicable disease over 4.8 million person-years a

240 n, the HIV epidemic, and increasing rates of non-communicable diseases, people in sub-Saharan Africa

241 onal Cancer Control Plans and six (27%) have non-communicable disease plans that include cancer.

242 f cardiovascular diseases, and commitment to non-communicable disease policy.

243 ient physical activity increases the risk of non-communicable diseases, poor physical and cognitive f

244 Cancer is one of the major non-communicable diseases posing a threat to world healt

245 e strategy of seeking natural factors in the non-communicable diseases prevention, but their sensory

246 Growing political recognition of non-communicable diseases provides a favourable politica

247 tralised, integrated care for severe chronic non-communicable diseases, provides an approach to servi

248 The rise in diabetes and other non-communicable diseases puts a heavy toll on health sy

249 ts among 10,040 Kurdish adults from Ravansar Non-Communicable Disease (RaNCD) cohort study in Iran.

250 m, so other strategies to address increasing non-communicable disease rates must be pursued.

251 years, due to population ageing, changes in non-communicable disease rates, and increasing air pollu

252 roups and regions, although communicable and non-communicable diseases remained the main causes of de

253 ers of diets associated with lower or higher non-communicable disease risk on the basis of multivaria

254 Deaths from non-communicable diseases rose by just under 8 million b

255 ated focus areas (other infectious diseases, non-communicable diseases, sector-wide approaches, and o

256 The communicable disease and non-communicable disease sectors need to move beyond con

257 olleagues argue that the long term impact of non-communicable diseases should be prioritised in plann

258 ement in the global monitoring framework for non-communicable diseases should promote accountability

259 associated with the damaging inflammation of non-communicable disease states and is considered an att

260 Treatment of non-communicable diseases such as cancer in refugees is

261 ion have been linked to an increased risk of non-communicable diseases such as cardiovascular disease

262 y adverse health conditions, including major non-communicable diseases such as coronary heart disease

263 ce of many pathologies, particularly chronic non-communicable diseases such as obesity and diabetes.

264 mensals are increasingly suggested to impact non-communicable diseases, such as inflammatory bowel di

265 osed and prescribed medicines for one of the non-communicable diseases targeted by the programme: hyp

266 Worldwide, communicable and non-communicable diseases tend to segregate geographical

267 e 2 diabetes mellitus (T2DM) are widespread, non-communicable diseases that are responsible for consi

268 es, coronary heart disease and other chronic non-communicable diseases that lower global life expecta

269 in infancy and childhood as well as chronic, non-communicable diseases that may manifest at any point

270 ical transitions from diseases of poverty to non-communicable diseases, the burden of disease and hea

271 er an accelerated rate of overall decline in non-communicable diseases, the poor-rich gap would widen

272 In various non-communicable diseases, the protective mode of the im

273 rant; University of New South Wales Medicine Non Communicable Diseases Theme Early-Mid Career Researc

274 ibute to worldwide epidemics of injuries and non-communicable diseases through traffic exposure, nois

275 dulate the risk of cardiometabolic and other non-communicable diseases through various mechanisms.

276 We used 11 physical non-communicable diseases to measure physical multimorbi

277 ions linking a broad set of risk factors for non-communicable diseases to parcel-wise CT and GMV acro

278 The burden of non-communicable diseases, to which cancer contributes g

279 g link between MQC and the onset of numerous non-communicable diseases, understanding the molecular r

280 Moreover, high costs for non-communicable diseases warrant new features for preve

281 An additional chronic non-communicable disease was associated with an increase

282 this age, whereas the mortality rate due to non-communicable diseases was 31 (16-45) per 100 000 per

283 onal lifestyle-based interventions for other non-communicable diseases, we highlight the potential of

284 Before 2005, cancer and other non-communicable diseases were not yet health and develo

285 sulin treatment, blood glucose level, having non-communicable diseases were significantly associated

286 Non-communicable diseases were the leading causes of dea

287 Most increases in DALYs, especially from non-communicable diseases, were due to population growth

288 prevalence of multiple and poorly controlled non-communicable diseases when older than 50 years.

289 untries (around 50% of DALYs attributable to non-communicable disease), whereas China more closely re

290 3.4 (SDG 3.4) to tackle the rising burden of non-communicable diseases, which calls for a reduction b

291 sk, 21 231 IPD-Work participants developed a non-communicable disease, while 101 319 UK Biobank parti

292 inger Ingelheim; Department of Management of Non-Communicable Diseases, WHO; and Population Health Re

293 In the present review, we address non-communicable diseases with a focus on cardiovascular

294 ed therapies include commonly used drugs for non-communicable diseases with good safety profiles, imm

295 in several health problems, including severe non-communicable diseases with potentially life-threaten

296 riority on addressing the high prevalence of non-communicable diseases, with variations in policies b

297 pheral artery disease is a prevalent chronic non-communicable disease without obvious symptoms.

298 nts for almost half of all deaths related to non-communicable disease worldwide, making it the single

299 Asthma is one of the most common chronic non-communicable diseases worldwide and is characterised

300 tions and accounts for the largest burden of non-communicable diseases worldwide.